| Symbol | GYRE |
|---|---|
| Name | GYRE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 12770 HIGH BLUFF DRIVE,SUITE 150, SAN DIEGO, California, 92130, United States |
| Telephone | +1 858 567-7770 |
| Fax | — |
| — | |
| Website | https://www.gyretx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001124105 |
| Description | Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States. Additional info from NASDAQ: |
(10% Negative) GYRE THERAPEUTICS, INC. (GYRE) Announces Delay in operations Trials for chronic hepatitis B (CHB)-induced liver fibrosis Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review
Read more📋 Ye Weiguo (Officer) plans to sell 300K shares of GYRE THERAPEUTICS, INC. (at $7.07 each, total $2.1M) Filed: May 11, 2026 | ID: 000001
Read moreLuo Ying 🔴 sold 10.3K shares of GYRE THERAPEUTICS, INC. (GYRE) at $8.04 Transaction Date: May 05, 2026 | Filing ID: 019658
Read moreNew Form 3 - GYRE THERAPEUTICS, INC. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001140361-26-019649 <b>Size:</b> 19 KB
Read moreNew Form 3 - GYRE THERAPEUTICS, INC. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001140361-26-019651 <b>Size:</b> 15 KB
Read moreNew Form 3 - GYRE THERAPEUTICS, INC. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001140361-26-019650 <b>Size:</b> 13 KB
Read moreNew Form 3 - GYRE THERAPEUTICS, INC. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001140361-26-019652 <b>Size:</b> 12 KB
Read moreGyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Read moreNew Form SCHEDULE 13D/A - GYRE THERAPEUTICS, INC. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001140361-26-019395 <b>Size:</b> 12 KB
Read moreGNI Group Ltd. 🟢 acquired 13.0M shares (2 derivative) of GYRE THERAPEUTICS, INC. (GYRE) Transaction Date: May 04, 2026 | Filing ID: 019378
Read more